NCT05757141 - An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2029

Conditions

Vanishing White Matter Disease

Interventions

DRUG

Fosigotifator

Oral Use

Trial Locations (5)

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

RECRUITING

Massachusetts General Hospital /ID# 270960, Boston

RECRUITING

University of Utah /ID# 255624, Salt Lake City

RECRUITING

McGill University Health Centre - Glen Site, Montreal

RECRUITING

Amsterdam UMC, locatie VUmc /ID# 270955, Amsterdam